Neurome has announced the expansion of its discovery research collaboration with Wyeth, which is currently focused on the investigation of certain aspects of CNS disease using Neurome's proprietary discovery technologies and expertise in quantitative neuropathology.
Under the terms of the expanded research collaboration, Neurome will evaluate the effectiveness of possible drug candidates as part of intervention studies in an animal model of neurodegenerative disease.
"Our partnership with Wyeth has been highly productive," commented Floyd E. Bloom, M.D., Chief Executive Officer, Chief Scientific Officer and Chairman of the Board of Neurome.
"We look forward to increasing our efforts with Wyeth to include the evaluation of potential therapeutic compounds to determine their effectiveness against neurodegenerative illnesses."
"The technology we have developed at Neurome is ideally suited to the comprehensive evaluation of drug candidates in preclinical animal models of disease," said Warren G. Young, Ph.D., President and Chief Operating Officer of Neurome.
"We are delighted that Wyeth has decided to expand the scope of its work with us to include these studies, which we believe will provide highly relevant data, useful in determining successful reversal of disease pathology."